Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Authors :: Fabrice Andre
Amparo Ruiz-Simon
Katherine E. Hutchinson
Antonio Llombart-Cussac
Vicente Guillem
Carlos L. Arteaga
Kyung Min Lee
Monica Arnedos
Monica V. Estrada
Ana Lluch
Joaquín Gavilá
Stefan Michiels
Alberto Servetto
Luigi Formisano
Daniel G. Stover
Valerie M. Jansen
Alejandro Pérez-Fidalgo
Thomas Stricker
Angel Guerrero-Zotano
Luis J. Schwarz
Jennifer M. Giltnane
Mohamed Amine Bayar
Source :: Clinical Cancer Research. 25:1431-1431
Publication Year :: 2019
Publisher :: American Association for Cancer Research (AACR), 2019.

Subjects :: Cancer Research
Oncology
business.industry
Letrozole
Cancer research
medicine
business
E2F4
medicine.drug

Tools